Open AccessPatients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment
Author(s) -
Marzia Del Re,
Paola Bordi,
Iacopo Petrini,
Eleonora Rofi,
Francesca Mazzoni,
Lorenzo Belluomini,
Enrico Vasile,
Giuliana Restante,
Francesco Di Costanzo,
Alfredo Falcone,
Antonio Frassoldati,
Ron H. N. van Schaik,
C.M.J. Steendam,
Antonio Chella,
Marcello Tiseo,
Riccardo Morganti,
Romano Danesi
Publication year - 2017
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.20947
Subject(s) - medicine , erasmus+ , oncology , family medicine , the renaissance , art history , art
NSCLC harboring activating mutations of EGFR is highly sensitive to first-line EGFR-tyrosine kinase inhibitors (TKIs), but drug resistance depending on the EGFR mutation p.T790M will occur in about 50-60% of patients. Detailed information on the amount of p.T790M plasmatic level associated with resistance to EGFR-TKIs and guidance to treatment with p.T790M-effective TKI depending on these levels, is lacking.